Gestonorone acetate
Clinical data
Other namesGestronol acetate; Norhydroxyprogesterone acetate; 17α-Hydroxy-19-norprogesterone 17α-acetate; 17α-Acetoxy-19-norprogesterone; 17α-Hydroxy-19-norpregn-4-ene-3,20-dione 17α-acetate
Drug classProgestin; Progestogen
Identifiers
  • [(8R,9S,10R,13S,14S,17R)-17-Acetyl-13-methyl-3-oxo-1,2,6,7,8,9,10,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-17-yl] acetate
CAS Number
PubChem CID
ChemSpider
UNII
CompTox Dashboard (EPA)
ECHA InfoCard100.046.242
Chemical and physical data
FormulaC22H30O4
Molar mass358.478 g·mol−1
3D model (JSmol)
  • CC(=O)[C@]1(CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CCC4=CC(=O)CC[C@H]34)C)OC(=O)C
  • InChI=1S/C22H30O4/c1-13(23)22(26-14(2)24)11-9-20-19-6-4-15-12-16(25)5-7-17(15)18(19)8-10-21(20,22)3/h12,17-20H,4-11H2,1-3H3/t17-,18+,19+,20-,21-,22-/m0/s1
  • Key:MTSLFKWJINJVBO-ZCPXKWAGSA-N

Gestonorone acetate, or gestronol acetate, also known as norhydroxyprogesterone acetate, is a progestin of the 19-norprogesterone and 17α-hydroxyprogesterone groups which was developed in the early 1960s but was never marketed.[1][2][3][4][5][6][7][8][9][10][11][12][13][14] It is the C17α acetate ester of gestronol (17α-hydroxy-19-norprogesterone).

Gestonorone acetate has been found to consistently inhibit ovulation at an oral dosage of 10 mg/day in combination with 50 μg/day oral ethinylestradiol.[15] Weak or no endometrial effects were observed at an oral dosage of 100 mg/day, basal vacuoles appeared at 130 to 140 mg/day, and full endometrial secretory transformation occurred at 220 mg/day.[16]

See also

References

  1. ↑ Noguchi S (1961). "Steroids. XX. Hydrolysis of steroidal esters by malt enzyme. 1. Selective hydrolysis of steroidal acetates". Yakugaku Zasshi. 81 (3): 369–373. doi:10.1248/yakushi1947.81.3_369. ISSN 0031-6903.
  2. ↑ Noguchi S (1961). "Steroids. XXIII Hydrolysis of steroidal esters by malt enzyme. 4. Synthesis of 17α,19-dihydroxyprogesterone and 17α-hydroxy-19-norprogesterone". Yakugaku Zasshi. 81 (3): 381–384. doi:10.1248/yakushi1947.81.3_381. ISSN 0031-6903.
  3. ↑ Dorfman RI, Kincl FA (1963). "Steroid anti-estrogens". Steroids. 1 (2): 185–209. doi:10.1016/S0039-128X(63)80136-1. ISSN 0039-128X.
  4. ↑ Suchowsky GK (April 1963). "Pregnancy-maintaining effect of synthetic progestogens in the rat". Acta Endocrinologica. 42 (4): 533–536. doi:10.1530/acta.0.0420533. PMID 13979052.
  5. ↑ Kalvoda J, Heusler K, Anner G, Wettstein A (1963). "Steroids. CXCVI. 19-Norsteroids. III. Synthesis of 19-norprogesterones". Helvetica Chimica Acta. 46: 1017–1029. doi:10.1002/hlca.19630460332. ISSN 0018-019X.
  6. ↑ Junkmann K (March 1963). "[Experimental viewpoints in the testing of synthetic gestagens]". Deutsche Medizinische Wochenschrift. 88 (13): 629–638. doi:10.1055/s-0028-1111990. PMID 13958089. S2CID 260098023.
  7. ↑ Kincl FA, Dorfman RI (1963). "Orally active steroidal ovulation inhibitors in the adult estrus rabbit". Steroids. 2 (5): 521–525. doi:10.1016/0039-128X(63)90029-1. ISSN 0039-128X.
  8. ↑ Suchowsky GK (1963). "Inhibition of ovulation by steroids". Journal of the Egyptian Medical Association. 1962–1963: 67–73. ISSN 0013-2411.
  9. ↑ Junkmann (1962). "The pharmacology of new gestational and anabolic steroids". Deutsch-Englische Medizinische Rundschau. 1 (4): 385–399. ISSN 0003-3332.
  10. ↑ Suchowsky GK, Baldratti G (September 1964). "Relationship Between Progestational Activity and Chemical Structure of Synthetic Steroids". The Journal of Endocrinology. 30 (2): 159–170. doi:10.1677/joe.0.0300159. PMID 14207040.
  11. ↑ Nevinny-Stickel J (1964). "Inhibition of ovulation determined by estimation of pregnanediol excretion". International Journal of Fertility. 9: 57–67. PMID 14106269.
  12. ↑ Jung H, Peters A (1967). "[The effect of various gestagens on the development of the fetus and rate of mortality in animal experiments]". Archiv Fur Gynakologie. 204 (1): 68–77. doi:10.1007/BF00668265. PMID 5630697. S2CID 22416963.
  13. ↑ Gilbert HG, Phillipps GH, English AF, Stephenson L, Woollett EA, Newall CE, Child KJ (April 1974). "The progestational and anti-estrogenic activities of some novel 11beta-substituted steroids". Steroids. 23 (4): 585–602. doi:10.1016/0039-128X(74)90010-5. PMID 4829347.
  14. ↑ Tang RR, Guo CC, Fan BL (2004). "Stereoselective asymmetric synthesis and characterization of 17α-acetyoxy-19-nor-progesterone". Journal of Central South University of Technology. 11 (3): 300–303. doi:10.1007/s11771-004-0061-y. ISSN 1005-9784. S2CID 195244927.
  15. ↑ Pincus G (3 September 2013). The Control of Fertility. Elsevier. pp. 222–. ISBN 978-1-4832-7088-3.
  16. ↑ Nevinny-Stickel J (1962). "Die gestagene Wirkung von Hydroxy-nor-Progesteronestern bei der Frau". Gewebs- und Neurohormone [The progestational effects of hydroxy-nor-progesterone esters in women]. Symposion der Deutschen Gesellschaft für Endokrinologie. Springer. pp. 248–255. doi:10.1007/978-3-642-86860-3_27. ISBN 978-3-540-02909-0. Nach oraler Verabreichung von 100 mg des Hydroxy-nor-ProgesteronAcetats sah man nur schwache oder noch keine gestagene Wirkung am Endometrium (Abb. 3). Nach der oralen Dosis von 130- 140 mg traten basale Vacuolen auf, nach 220 mg war - außer bei einer Patientin mit individuell geringerer Ansprechbarkeit des Endometriums (2) - eine volle sekretorische Umwandlung erreicht: [...]
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.